REFERENCES
- Collaborative Normal‐Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal‐tension glaucoma. Am J Ophthalmol 1998; 126: 498–505.
- Collaborative Normal‐Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated normal‐tension and those whose pressures were therapeutically reduced. Am J Ophthalmol 1998; 126: 487–497.
- Caprioli J. Editorial. The treatment of normal‐tension glaucoma. Am J Ophthalmol 1998; 126:578–581.
- Drance S. Guest editorial. The Collaborative Normal‐Tension Glaucoma Study and some of its lessons. Can J Ophthalmol 1999; 34: 1–6.
- Osborne NN, Cazevielle C, Carcalho AL et al. In vivo and in vitro experiments show that betaxolol is a retinal neuroprotective agent. Brain Res 1997; 751: 113–123.
- Burke J, Schwartz M. Preclinical evaluation of brimonidine. Surv Ophthalmol 1996; 41: Supp 1.S9–S18.
- Netland PA, Chaturvedi N, Dreyer EB. Calcium channel blockers in the management of low tension and open angle glaucoma. Am J Ophthalmol 1993; 115: 608–613.
- Dreyer EB, Lipton SA. A proposed role for excitatory amino acids in glaucoma visual loss. Invest Ophthalmol Vis Sci. 1993: suppl 1504.
- Flammer J, Collignon‐brach P, Demailly A et al. Long‐term visual field follow up in betaxolol and timolol treated patients. Perim Updates 199293; 147–152.